Cancer Genetics

The lawsuits allege the company made false and/or misleading statement and/or failed to disclose information that was pertinent to investors.

The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.

The companies will join their respective technologies into a precision oncology testing and analysis offering.

Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.

The program enables NJ-based tech firms to sell net operating losses and R&D tax credits for at least 80 percent of the value of the tax benefits.

The test, which also is FDA-approved, can be used to identify best responders to three non-small cell lung cancer treatment regimens.

The company plans to offer 3.5 million units, comprising one share of common stock and one warrant to buy an additional share, at $2 per unit.

The partners will collaborate on educational and collaborative oncology clinical research activities in India to drive use of genomic technologies.

The revenue increase was primarily driven by increased revenue in the company's biopharma services, clinical services, and discovery services divisions.